NDAORALTABLET
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEMIXYS is a fixed-dose combination tablet containing lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy. This oral combination is indicated for the treatment of HIV-1 infection in adult patients. The dual mechanism targets viral reverse transcriptase to suppress HIV replication.
Peak
Product is in peak commercial stage with established market presence; teams are focused on market maintenance and optimization rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEMIXYS provides exposure to mature market dynamics, payer negotiations, and established patient populations within HIV care. Career growth opportunities lean toward commercial optimization, market access strategy, and relationship management with healthcare providers and insurers in the established HIV therapeutic space.
Brand ManagerMedical Science Liaison
Worked on TEMIXYS at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.